Altimmune Investor Relations Material
Latest events
Study Result
Altimmune
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Altimmune Inc
Access all reports
Altimmune, Inc. engages in the development of immunotherapeutics for infectious and chronic diseases. The company focuses on the development of vaccines and therapeutics for influenza, anthrax and COVID-19. It offers HepTcell, a vaccine candidate to treat Chronic Hepatitis B; AdCOVID, which is an intranasal antigen vaccine to fight COVID-19; NasoVAX, a single dose flu vaccine; T-COVID, an intranasal immune modulating therapeutic candidate; and NasoShield, an anthrax vaccine product candidate. The company was founded by Vipin K. Garg on April 15, 2005 and is headquartered in Gaithersburg, MD.
Key slides for Altimmune Inc
Corporate Presentation
Altimmune Inc
Corporate Presentation
Altimmune Inc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
ALT
Country
🇺🇸 United States